STING1 and non-small cell lung carcinoma: Studies have revealed that enhanced hypoxia-inducible factor 1-alpha (HIF-1α)-mediated glycolytic metabolism in DCs treated with the STING agonist cGAMP amplifies their antitumor efficacy, with elevated glycolysis further promoting STING signaling in human non-small cell lung cancer (NSCLC), creating a positive feedback loop.27